Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?

The introduction of kinase inhibitors in cancer medicine has transformed chronic myeloid leukemia from a fatal disease into a leukemia subtype with a favorable prognosis by interfering with the constitutively active kinase BCR-ABL. This success story has resulted in the development of multiple kinas...

Full description

Saved in:
Bibliographic Details
Published in:Cellular and molecular life sciences : CMLS 2015-10, Vol.72 (19), p.3589-3598
Main Authors: van der Sligte, Naomi E, Kampen, Kim R, de Bont, Eveline S. J. M
Format: Article
Language:English
Subjects:
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cancer
Cell Biology
Child
drugs
Humans
Inhibitors
intracellular signaling peptides and proteins
Kinases
Leukemia
Life Sciences
medicine
myeloid leukemia
Neoplasms - drug therapy
Pediatrics
Pharmaceutical sciences
Precision Medicine - trends
prognosis
Protein Kinase Inhibitors - therapeutic use
Protein Kinases - genetics
Proteomics
Proteomics - methods
Proteomics - trends
Signal Transduction - drug effects
Signal Transduction - physiology
Visions and Reflections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The introduction of kinase inhibitors in cancer medicine has transformed chronic myeloid leukemia from a fatal disease into a leukemia subtype with a favorable prognosis by interfering with the constitutively active kinase BCR-ABL. This success story has resulted in the development of multiple kinase inhibitors. We are currently facing significant limitations in implementing these kinase inhibitors into the clinic for the treatment of pediatric malignancies. As many hallmarks of cancer are known to be regulated by intracellular protein signaling networks, we suggest focusing on these networks to improve the implementation of kinase inhibitors. This viewpoint will provide a short overview of currently used strategies for the implementation of kinase inhibitors as well as reasons why kinase inhibitors have unfortunately not yet been widely used for the treatment of pediatric cancers. We argue that by using a future personalized medicine strategy combining kinomics, proteomics, and drug screen approaches, the gap between pediatric cancers and the use of kinase inhibitors may be bridged.
ISSN:1420-682X
1420-9071
DOI:10.1007/s00018-015-2019-7